[Form 4] Akoya BioSciences, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Form 4 highlights the final disposition of Akoya Biosciences, Inc. (AKYA) equity held by Chief Legal Officer Jennifer Kamocsay following the 8 July 2025 closing of the company’s merger with Quanterix Corporation.

• All AKYA common shares outstanding were converted into the right to receive 0.1461 share of Quanterix common stock plus $0.38 in cash per AKYA share (subject to potential adjustments).
• The reporting person’s 16,772 directly-held AKYA shares and 162,500 unvested RSUs were reported as dispositions under transaction code “J”.
• Two outstanding employee stock-option grants for 75,000 shares at $7.60 and 70,000 shares at $5.35 were accelerated and subsequently cancelled for no consideration because their exercise prices were equal to or above the per-share merger consideration.
• After the transactions, the filing shows 0 AKYA securities remaining beneficially owned; AKYA is now a wholly owned subsidiary of Quanterix.

The filing is procedural, documenting equity conversion mechanics rather than open-market trading, and confirms that the merger has formally closed and that AKYA equity has ceased to trade independently.

Insights

M&A Specialist

TL;DR: Filing confirms Akoya–Quanterix merger close; all insider AKYA equity converted or cancelled.

This Form 4 is a mechanical post-closing disclosure. It shows that Kamocsay’s common shares and RSUs were exchanged for the agreed mix of Quanterix stock and cash, while underwater options were cancelled. Such treatment is conventional and suggests the merger terms were executed exactly as negotiated—no surprises in consideration mix, conversion ratio, or vesting treatment. For Akoya holders the value crystallised at 0.1461 QTRX + $0.38 per share; for Quanterix, share issuance is limited and was already contemplated in the merger model. Market impact is minimal because the transaction had been disclosed previously and AKYA stock will no longer trade.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McKelligon Brian

(Last) (First) (Middle)

C/O AKOYA BIOSCIENCES, INC.

100 CAMPUS DRIVE, 6TH FLOOR

(Street)

MARLBOROUGH MA 01752

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Akoya Biosciences, Inc. [ AKYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/08/2025		J(1)		393,338(2)	A	(2)	813,464	D
Common Stock	07/08/2025		J(1)		331,090(2)	A	(2)	1,144,554	D
Common Stock	07/08/2025		F		196,866(2)	D	(2)	947,688	D
Common Stock	07/08/2025		J(3)		947,688(4)	D	(4)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$0.3029	07/08/2025		J(1)			393,338	(2)	11/09/2027	Common Stock	393,338	$0	0	D
Employee Stock Option (Right to Buy)	$0.4427	07/08/2025		J(1)			331,090	(2)	05/02/2029	Common Stock	331,090	$0	0	D
Employee Stock Option (Right to Buy)	$16.12	07/08/2025		J(5)			241,592	(6)	03/24/2031	Common Stock	241,592	$0	0	D
Employee Stock Option (Right to Buy)	$11.88	07/08/2025		J(5)			160,000	(6)	03/23/2032	Common Stock	160,000	$0	0	D
Employee Stock Option (Right to Buy)	$12.3	07/08/2025		J(5)			160,000	(6)	02/23/2033	Common Stock	160,000	$0	0	D
Employee Stock Option (Right to Buy)	$5.35	07/08/2025		J(5)			175,000	(6)	02/22/2034	Common Stock	175,000	$0	0	D

Explanation of Responses:

1. Cashless exercise of options pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the "Merger Agreement"), by and among Quanterix Corporation, a Delaware corporation ("Quanterix"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix ("Merger Sub"), and the Issuer. On July 8, 2025 (the "Closing Date"), Merger Sub merged with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix.

2. Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price less than the value of the Per Share Merger Consideration (as defined below) was automatically cashless exercised.

3. Disposition of shares pursuant to Merger Agreement.

4. In connection with the terms of the Merger Agreement, each share of common stock of Issuer outstanding on the Closing Date was converted into the right to receive (a) 0.1461 of a share of common stock of Quanterix (the "Per Share Stock Consideration") and (b) $0.38 in cash, without interest (the "Per Share Cash Consideration" and together with the Per Share Stock Consideration, the "Per Share Merger Consideration"). Each of the Per Share Stock Consideration and the Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement.

5. Disposition of options pursuant to the Merger Agreement.

6. Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration.

	/s/ Brian McKelligon	07/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.